Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk? - PubMed

18 hours ago

Obesity increases the risk of at least 13 adult cancer types and is a major cause of cancer, second only to tobacco in many populations.
Intentional weight loss's impact on reducing cancer risk remains uncertain, but bariatric surgery studies show that sustained weight loss of 20% to 30% in severe obesity lowers obesity-related cancer risk over 10 years.
GLP-1 receptor agonists, such as semaglutide and tirzepatide, have been shown in randomized trials to cause significant weight loss (around 15%) in obese individuals with or without diabetes, revolutionizing obesity management.
There is a strong rationale for evaluating incretin-mimetic drugs in cancer prevention trials due to their weight loss effects, but the feasibility of such trials is currently questionable.

Hasty Briefsbeta